A pragmatic pipeline for drug resistance and lineage identification in Mycobacterium tuberculosis using whole genome sequencing
- PMID: 39928651
- PMCID: PMC11809915
- DOI: 10.1371/journal.pgph.0004099
A pragmatic pipeline for drug resistance and lineage identification in Mycobacterium tuberculosis using whole genome sequencing
Erratum in
-
Correction: A pragmatic pipeline for drug resistance and lineage identification in Mycobacterium tuberculosis using whole genome sequencing.PLOS Glob Public Health. 2025 Aug 21;5(8):e0005093. doi: 10.1371/journal.pgph.0005093. eCollection 2025. PLOS Glob Public Health. 2025. PMID: 40839559 Free PMC article.
Abstract
Delays in accurate diagnosis of drug resistant tuberculosis (DR-TB) can hinder treatment. Whole genome sequencing (WGS) provides more information than standard molecular and phenotypic testing, but commonly used platforms are expensive to implement, and data interpretation requires significant expertise. We aimed to optimise a TB WGS diagnostic pipeline balancing user-friendliness, cost-effectiveness and time to results, whilst ensuring accuracy. Growth conditions, DNA extraction protocols and Oxford Nanopore Technologies (ONT) library preparation kits were compared. ONT was compared with Illumina protocols. Software for basecalling and analysis were evaluated to find the most accurate resistance SNP and lineage predictor. Optimally, a spin-column CTAB DNA extraction method was combined with the RBK110.96 library preparation kit, high accuracy (HAC) basecalling and data analysis using TB-Profiler. Compared with Illumina, the pipeline was concordant for 16/17 (94%) isolates (lineage) and for 17/17 (100%) isolates (resistance SNPs). Our pipeline was 71% (12/17) concordant with phenotypic drug susceptibility test (DST) results. Time-to-diagnosis was around four weeks. This optimised TB sequencing pipeline requires less time and expertise to run and analyse than Illumina, takes less time than phenotypic DSTs and the results are comparable with Illumina. The cost per sample is comparable with other methods. These features make it an important tool for incorporating into routine DR-TB diagnostic pipelines and larger scale drug resistance surveillance in all settings.
Copyright: © 2025 Elton et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Conflict of interest statement
This project obtained technical support from Oxford Nanopore Technologies Ltd (ONT), but ONT did not contribute financially to the study.
Figures







References
-
- Thwaites G, Nguyen NV. Linezolid for drug-resistant tuberculosis. New Engl J Med. 2022;387(9):842–3. - PubMed
-
- World Health Organization. Global tuberculosis report 2019. World Health Organization. 2019.
-
- World Health Organization. Global tuberculosis report. World Health Organization. 2016.
-
- World Health Organization. Global tuberculosis report. World Health Organization. 2021.
LinkOut - more resources
Full Text Sources